Skip to main content

Stemcell Holdings, Inc. (STMM)

New York Stock Exchange Healthcare BiotechnologyView data quality →
69.5Fair

ValueMarkers Composite Index

Top 99%#535 of 44,722
Undervalued

100% below intrinsic value ($30)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-1.59
High Risk
Altman
4.52
Safe
DCF Value
$30
Undervalued
ROIC
63.3%
Strong
P/E
0.7
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Stemcell Holdings, Inc. (STMM) — VMCI valuation read

Across 120 indicators, Stemcell Holdings, Inc. (STMM) lands at VMCI 70/100. The Healthcare sector median is 50, so the 20-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on STMM in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, STMM trades at 17.0x earnings, 6% below the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of -1.8x leaves covenant headroom for STMM on the trailing balance sheet.

STMM rose 3.1% over the trailing 7 days, with a -22.5% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.